Melanotan I
Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone studied for its effects on melanin production and skin pigmentation. Research has focused on light sensitivity, photoprotection, ultraviolet exposure, and the skin’s response to cellular damage.
MELANOTAN I AT A GLANCE
WHAT IS Melanotan I?
Melanotan I is a synthetic peptide modeled after alpha-melanocyte-stimulating hormone, commonly called alpha-MSH. It contains 13 amino acids and includes two structural changes that make it more stable and longer-lasting than the naturally occurring hormone.
Melanotan I is also known by its pharmaceutical name, afamelanotide. A controlled-release afamelanotide implant is approved under the name Scenesse for adults with erythropoietic protoporphyria, or EPP. This approved implant should not be confused with unapproved Melanotan I products sold for tanning or general research purposes.
HOW DOES MELANOTAN I WORK?
Melanotan I activates the melanocortin-1 receptor, or MC1R, found primarily on pigment-producing cells called melanocytes. This receptor activity encourages the production of eumelanin, a darker form of melanin that absorbs and disperses some ultraviolet radiation.
Increased eumelanin can darken the skin and strengthen its natural response to light exposure. Melanocortin signaling may also influence antioxidant activity, inflammation, and cellular responses to ultraviolet damage, although these effects remain under investigation and do not replace ordinary sun protection.
Areas of Research
Melanotan I research centers on pigmentation and light sensitivity, with additional interest in the wider protective and regulatory functions of melanocortin signaling within the skin.
PIGMENTATION AND MELANIN PRODUCTION
Examining melanocyte activity, eumelanin production, changes in skin color, and differences in response among various skin types.
LIGHT SENSITIVITY AND PHOTOPROTECTION
Studying whether increased pigmentation allows people with certain photosensitivity disorders to tolerate light exposure more comfortably.
ULTRAVIOLET RESPONSE
Exploring oxidative stress, inflammation, DNA damage, and cellular repair following controlled ultraviolet exposure.
PIGMENT-RELATED SKIN CONDITIONS
Investigating possible applications involving vitiligo and other conditions where pigmentation or sensitivity to light is altered.
Research Highlights
Human trials found that controlled-release afamelanotide implants increased pain-free light exposure in adults with erythropoietic protoporphyria, leading to FDA approval for that specific use. Research has also examined pigmentation, ultraviolet-induced cellular damage, and afamelanotide alongside narrowband UVB therapy for vitiligo. The FDA-approved implant is not approved as a cosmetic tanning treatment, and increased pigmentation does not provide complete protection against ultraviolet radiation or eliminate the need for sun protection.
WHAT IS MELANOTAN I MOST COMMONLY RESEARCHED FOR?
Melanotan I is most commonly studied for its ability to stimulate melanin production through MC1R. Researchers examine how increased eumelanin affects pigmentation, sensitivity to light, and the skin’s response to ultraviolet exposure. Its strongest clinical evidence involves adults with erythropoietic protoporphyria rather than cosmetic tanning.
HOW DOES MELANOTAN I FIT INTO PEPTIDE RESEARCH?
Melanotan I is part of the melanocortin family of peptide analogs. These compounds are modeled after naturally occurring hormones that influence pigmentation, inflammation, appetite, energy balance, and other biological functions. Melanotan I primarily attracts attention for its activity involving MC1R and melanin production.
WHAT MAKES MELANOTAN I UNIQUE?
Melanotan I is more stable and longer-lasting than natural alpha-MSH while retaining strong activity involving pigmentation. It is also one of the few compounds commonly found in peptide research libraries that has an FDA-approved pharmaceutical form. That approval applies only to the regulated afamelanotide implant and its specific indication, not to other Melanotan I formulations.
HOW IS MELANOTAN I DIFFERENT FROM MELANOTAN II?
Both compounds were developed from alpha-MSH, but their structures and biological activity differ. Melanotan I is a linear peptide associated primarily with MC1R activity and pigmentation. Melanotan II is a shorter cyclic analog that interacts more broadly with several melanocortin receptors, creating additional research interest involving appetite and sexual function.
WHAT HAVE RESEARCHERS LEARNED ABOUT MELANOTAN I SO FAR?
Researchers have learned that Melanotan I can produce increased pigmentation and improve tolerance to light in people with EPP when delivered through the approved controlled-release implant. Studies have also identified changes involving freckles, moles, and other pigmented areas, which is why the FDA labeling recommends regular skin examinations. Broader claims involving tanning, UV protection, or other skin conditions are not supported by the same level of evidence.
IS RESEARCH ON MELANOTAN I CONTINUING TODAY?
Yes. Researchers continue studying afamelanotide in relation to photosensitivity disorders, vitiligo, ultraviolet damage, DNA-repair responses, oxidative stress, and other pigment-related conditions. Current work is also exploring how melanocortin signaling may protect skin cells beyond simply increasing visible pigmentation.